<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
______________
Date of Report (Date of earliest event reported): January 16, 2001
CuraGen Corporation
(Exact name of registrant as specified in its charter)
Delaware 0-23223 06-1331400
-------- ------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
555 Long Wharf Drive, 11th Floor
New Haven, Connecticut 06511
--------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (203) 401-3330
<PAGE>
ITEM 5. OTHER EVENTS.
On January 16, 2001, the Registrant issued a press release announcing that
it had entered into two landmark biotechnology agreements with Bayer AG. The
first agreement is a comprehensive alliance to discover, develop, and jointly
commercialize small molecule drugs to treat obesity and adult onset diabetes.
The second agreement is a broad collaboration to apply the Registrant's
functional genomic technologies and pharmacogenomic expertise to evaluate
Bayer's developmental and preclinical pipeline of pharmaceutical compounds
across all disease areas. In addition, the second agreement includes an $85
million equity investment in the Registrant by Bayer. One or both of these
agreements may be subject to Hart-Scott-Rodino approval. A copy of the press
release is attached to this Current Report on Form 8-K as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1 - Press Release dated January 16, 2001.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CURAGEN CORPORATION
(Registrant)
Date: January 16, 2001 By: /s/ David Wurzer
-----------------
Executive Vice President and
Chief Financial Officer
3
